Abstract: The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.

Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.

Abstract: The present invention relates to binding protein-toxin conjugates comprising one or more anthracycline toxin moieties, and the use thereof in immunooncological applications.

Abstract: The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.

Abstract: This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the A1 domain of tenascin C or the ED-A or ED-B isoforms of fibronectin. The antibody molecules may be positioned at the N and C terminals of the IL4. The immunoconjugate may be useful in the treatment of cancer, inflammatory autoimmune disease and other disease characterised by expression of an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling.

Abstract: The invention relates to the diagnosis and treatment of diseases, including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.

Abstract: This invention relates to methods and compositions, in a combination therapy, for treatment of neoplastic disease, including tumors and cancer, wherein an immunocytokine and a small molecule drug conjugate which comprises a moiety capable of binding to a tumor-associated target, e.g., capable of binding to carbonic anhydrase IX (CAIX), are administered. In preferred embodiments, the immunocytokine comprises an antibody targeting the ED-B or ED-A domain of fibronectin and interleukin-2, and the small molecule drug conjugate comprises a ligand moiety capable of binding to CAIX, a linker, and a cytotoxic drug.

Abstract: The present invention relates to the treatment of intestinal diseases and disorders, such as inflammatory bowel disease (IBD). The invention involves antibodies and the use of antibodies which bind antigens that have been shown to be over-expressed in the intestine compared to other organs, including antigens cadherin-17, anterior gradient protein 2 homolog, galectin-4, and galectin-2. The antibodies may be conjugated to anti-inflammatory or immunosuppressive agents, as required.

Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.

Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.

Abstract: The invention relates to the diagnosis and treatment of diseases,including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.

Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.

Abstract: A targeted therapeutic agent comprising a compound of formula: B-L-D wherein: B is a non-internalizing binding moiety specific for a cancer associated protein; D is a cytotoxic drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The binding moiety is a ligand for the cancer associated protein whereby drawbacks associated with the use of internalizing ligands are avoided.